EA201591324A1 - Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета - Google Patents
Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелетаInfo
- Publication number
- EA201591324A1 EA201591324A1 EA201591324A EA201591324A EA201591324A1 EA 201591324 A1 EA201591324 A1 EA 201591324A1 EA 201591324 A EA201591324 A EA 201591324A EA 201591324 A EA201591324 A EA 201591324A EA 201591324 A1 EA201591324 A1 EA 201591324A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- prevention
- treatment
- growth
- fibrobal
- fgr3
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 238000000354 decomposition reaction Methods 0.000 title 1
- 230000012010 growth Effects 0.000 title 1
- 239000003102 growth factor Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 4
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010008723 Chondrodystrophy Diseases 0.000 abstract 1
- 208000008919 achondroplasia Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000009645 skeletal growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2013/001480 WO2014111744A1 (en) | 2013-01-16 | 2013-01-16 | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201591324A1 true EA201591324A1 (ru) | 2016-01-29 |
Family
ID=48289519
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201591324A EA201591324A1 (ru) | 2013-01-16 | 2013-01-16 | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| EA201591055A EA201591055A1 (ru) | 2013-01-16 | 2014-01-16 | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201591055A EA201591055A1 (ru) | 2013-01-16 | 2014-01-16 | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20150344855A1 (enExample) |
| EP (2) | EP2945967B1 (enExample) |
| JP (3) | JP2016506914A (enExample) |
| KR (3) | KR20160002681A (enExample) |
| CN (1) | CN105121464B (enExample) |
| AU (2) | AU2013373679A1 (enExample) |
| CA (2) | CA2898415A1 (enExample) |
| DK (1) | DK2945967T3 (enExample) |
| EA (2) | EA201591324A1 (enExample) |
| ES (1) | ES2796743T3 (enExample) |
| HU (1) | HUE049556T2 (enExample) |
| IL (2) | IL239810A0 (enExample) |
| MX (2) | MX372787B (enExample) |
| PE (1) | PE20151664A1 (enExample) |
| PL (1) | PL2945967T3 (enExample) |
| PT (1) | PT2945967T (enExample) |
| SG (2) | SG11201505488XA (enExample) |
| SI (1) | SI2945967T1 (enExample) |
| WO (2) | WO2014111744A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201591324A1 (ru) | 2013-01-16 | 2016-01-29 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| CA2972865A1 (en) | 2015-01-07 | 2016-07-14 | Therachon Sas | Soluble fgfr3 decoys for treating skeletal growth disorders |
| KR20170121719A (ko) * | 2016-04-25 | 2017-11-02 | 장부다 | Vr 공간에서 사용자 인터페이스를 제공하는 방법, 디바이스 및 기록매체 |
| WO2018007597A1 (en) | 2016-07-07 | 2018-01-11 | Therachon | Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof |
| MX2020003114A (es) * | 2017-09-20 | 2020-10-20 | Pfizer | Tratamiento de deposicion anormal de grasa visceral utilizando polipeptidos de receptor 3 de factor de crecimiento de fibroblastos soluble (sfgfr3). |
| CN108410803B (zh) * | 2018-03-28 | 2019-02-05 | 湖南源品细胞生物科技有限公司 | 一种诱导脂肪干细胞成软骨分化的培养方法和培养液 |
| CN110272900B (zh) * | 2019-04-19 | 2024-03-26 | 中国人民解放军陆军军医大学 | 用于制备骨骼发育异常猪模型的sgRNA及其应用 |
| WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
| JP2022184798A (ja) | 2021-06-01 | 2022-12-13 | ファイザー・インク | ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
| DE69619526T2 (de) | 1995-06-12 | 2002-10-31 | Yeda Research And Development Co., Ltd. | Fgf9 als spezifischer ligand für fgfr3 |
| US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
| US7029872B2 (en) | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
| US7863020B2 (en) | 2000-06-28 | 2011-01-04 | Glycofi, Inc. | Production of sialylated N-glycans in lower eukaryotes |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| CA2432257A1 (en) * | 2000-12-18 | 2002-06-27 | Gene Logic, Inc. | Treatment of bone disorders by modulation of fgfr3 |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| AU2002314495A1 (en) | 2001-06-20 | 2003-01-02 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| JP4252746B2 (ja) * | 2001-10-05 | 2009-04-08 | 一和 中尾 | 軟骨無形成症治療剤 |
| JP2003104908A (ja) * | 2001-09-28 | 2003-04-09 | Ichikazu Nakao | 軟骨無形成症治療剤 |
| BRPI0203172B8 (pt) * | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| US7332299B2 (en) | 2003-02-20 | 2008-02-19 | Glycofi, Inc. | Endomannosidases in the modification of glycoproteins in eukaryotes |
| IL156495A0 (en) * | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| JP4970057B2 (ja) * | 2004-02-24 | 2012-07-04 | アラーガン、インコーポレイテッド | ボツリヌス毒素スクリーニングアッセイ |
| EP1910542B1 (en) * | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| CA2655504A1 (en) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| CA2664921A1 (en) | 2006-09-28 | 2008-04-03 | Hepacore Ltd. | N-terminal fgf variants having increased receptor selectivity and uses thereof |
| CL2007003411A1 (es) | 2006-11-28 | 2008-07-04 | Centelion | Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu |
| WO2008133873A2 (en) * | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| US8426396B2 (en) | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
| WO2010002862A2 (en) | 2008-07-01 | 2010-01-07 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
| CA2732449A1 (en) | 2008-08-04 | 2010-02-11 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
| TWI381848B (zh) | 2008-10-20 | 2013-01-11 | Imclone Llc | 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物 |
| PE20120553A1 (es) | 2009-03-25 | 2012-05-18 | Genentech Inc | Anticuerpos anti-fgfr3 |
| CN101585866B (zh) * | 2009-07-02 | 2011-10-05 | 中国人民解放军第三军医大学野战外科研究所 | 调节fgfr3活性的多肽及其筛选方法和应用 |
| US8445445B2 (en) | 2009-09-15 | 2013-05-21 | Five Prime Therapeutics, Inc. | Method of promoting hair growth using FGFR4 extracellular domains |
| ES2600631T3 (es) | 2009-11-13 | 2017-02-10 | Five Prime Therapeutics, Inc. | Uso de proteínas del dominio extracelular de FGFR1 para tratar cánceres caracterizados por mutaciones activadoras dependientes de ligando en FGFR2 |
| US8685931B2 (en) | 2009-12-17 | 2014-04-01 | Five Prime Therapeutics, Inc. | Hair growth methods using FGFR3 extracellular domains |
| US20120328599A1 (en) | 2010-01-14 | 2012-12-27 | Yale University | Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| EP2658979B1 (en) * | 2010-12-27 | 2018-02-14 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
| CN102219860B (zh) | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| BR112014009797A2 (pt) | 2011-10-24 | 2020-10-27 | Halozyme, Inc. | diagnóstico de companhia para terapia de agente anti-hialuronano e métodos de uso do mesmo |
| FR2984325A1 (fr) | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| AU2013295805B2 (en) | 2012-07-24 | 2019-05-02 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| CA2878183A1 (en) | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
| AU2013337264B2 (en) | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| EA201591324A1 (ru) | 2013-01-16 | 2016-01-29 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| PE20170256A1 (es) | 2014-01-24 | 2017-04-22 | Ngm Biopharmaceuticals Inc | Proteinas de union y sus metodos de uso |
| CA2972865A1 (en) | 2015-01-07 | 2016-07-14 | Therachon Sas | Soluble fgfr3 decoys for treating skeletal growth disorders |
| WO2018007597A1 (en) | 2016-07-07 | 2018-01-11 | Therachon | Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof |
| MX2020003114A (es) | 2017-09-20 | 2020-10-20 | Pfizer | Tratamiento de deposicion anormal de grasa visceral utilizando polipeptidos de receptor 3 de factor de crecimiento de fibroblastos soluble (sfgfr3). |
-
2013
- 2013-01-16 EA EA201591324A patent/EA201591324A1/ru unknown
- 2013-01-16 KR KR1020157022203A patent/KR20160002681A/ko not_active Withdrawn
- 2013-01-16 CA CA2898415A patent/CA2898415A1/en not_active Abandoned
- 2013-01-16 AU AU2013373679A patent/AU2013373679A1/en not_active Abandoned
- 2013-01-16 SG SG11201505488XA patent/SG11201505488XA/en unknown
- 2013-01-16 US US14/759,490 patent/US20150344855A1/en not_active Abandoned
- 2013-01-16 JP JP2015553175A patent/JP2016506914A/ja not_active Withdrawn
- 2013-01-16 WO PCT/IB2013/001480 patent/WO2014111744A1/en not_active Ceased
-
2014
- 2014-01-16 HU HUE14702206A patent/HUE049556T2/hu unknown
- 2014-01-16 CA CA2896978A patent/CA2896978A1/en active Pending
- 2014-01-16 KR KR1020157022078A patent/KR102249454B1/ko not_active Expired - Fee Related
- 2014-01-16 AU AU2014206844A patent/AU2014206844A1/en not_active Abandoned
- 2014-01-16 PE PE2015001353A patent/PE20151664A1/es not_active Application Discontinuation
- 2014-01-16 CN CN201480005077.6A patent/CN105121464B/zh not_active Expired - Fee Related
- 2014-01-16 MX MX2015009142A patent/MX372787B/es active IP Right Grant
- 2014-01-16 JP JP2015553074A patent/JP2016506912A/ja not_active Withdrawn
- 2014-01-16 WO PCT/EP2014/050800 patent/WO2014111467A1/en not_active Ceased
- 2014-01-16 EP EP14702206.5A patent/EP2945967B1/en active Active
- 2014-01-16 ES ES14702206T patent/ES2796743T3/es active Active
- 2014-01-16 US US14/759,535 patent/US10724014B2/en not_active Expired - Fee Related
- 2014-01-16 EA EA201591055A patent/EA201591055A1/ru unknown
- 2014-01-16 PT PT147022065T patent/PT2945967T/pt unknown
- 2014-01-16 EP EP20167861.2A patent/EP3736285A1/en not_active Withdrawn
- 2014-01-16 KR KR1020217013228A patent/KR20210054026A/ko not_active Withdrawn
- 2014-01-16 SI SI201431607T patent/SI2945967T1/sl unknown
- 2014-01-16 PL PL14702206T patent/PL2945967T3/pl unknown
- 2014-01-16 DK DK14702206.5T patent/DK2945967T3/da active
- 2014-01-16 SG SG11201505140XA patent/SG11201505140XA/en unknown
-
2015
- 2015-07-06 IL IL239810A patent/IL239810A0/en unknown
- 2015-07-15 MX MX2019013857A patent/MX2019013857A/es unknown
- 2015-07-16 IL IL239996A patent/IL239996A0/en unknown
-
2019
- 2019-02-08 JP JP2019021752A patent/JP6995069B2/ja not_active Expired - Fee Related
- 2019-08-05 US US16/532,184 patent/US20200199545A1/en not_active Abandoned
-
2020
- 2020-03-13 US US16/818,954 patent/US11702642B2/en active Active
- 2020-06-19 US US16/906,046 patent/US11814654B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591324A1 (ru) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета | |
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015502788A1 (en) | Antibody formulations and methods | |
| SG10201809427SA (en) | Insulin receptor partial agonists | |
| SG10201808053XA (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| JO3475B1 (ar) | ناهضات مستقبل سوماتوستاتين نوع فرعي 4 (sstr4) جديدة | |
| MX2021014242A (es) | Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora. | |
| MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
| BR112016012840A2 (pt) | Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre | |
| ZA202503388B (en) | Semaglutide in medical therapy | |
| SA516370641B1 (ar) | مركبات حلقية غير متجانسة وطرق لاستخدامها | |
| NZ713080A (en) | Pyridin-4-yl derivatives | |
| JO3367B1 (ar) | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 | |
| PH12015502820A1 (en) | Nanoparticulate formulation comprising a trpa1 antagonist | |
| MX368641B (es) | Compuestos para el tratamiento de inflamación y dolor. | |
| PH12022551548A1 (en) | Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof | |
| SG10201809418VA (en) | New administration routes of insulin, insulin analogs or derivatives of insulin | |
| PL407393A1 (pl) | Nowe lipoaminokwasy zawierające biogenne aminokwasy oraz ich zastosowanie | |
| HUE050632T2 (hu) | P13K aktivitását vagy funkcióját gátló inhibitorok alkalmazása primer Sjögren-szindróma kezelésére | |
| LV14884A (lv) | 1,4-dihidropiridin-4-il-piridīnija atvasinājumi kā jauni adenozīna A2A receptora agoallostēriskie modulatori | |
| UA89713U (ru) | Способ ранней реабилитации детей после перенесенной внегоспитальной пневмонии | |
| UA84195U (ru) | Способ лечения гриппа у взрослых |